BioCentury® Workspace helps subscribers get the most out of their subscription.

• Create your own feed using filters and keywords
• Manage custom email alerts
• Access personal folders containing your saved articles

💡In recognition of Breast Cancer Awareness Month, explore BioCentury's analysis of where breast cancer treatment is heading next. Oral selective estrogen receptor degraders (SERDs) have become one of the most advanced proving grounds for targeted protein degradation, and the bar for differentiation is rising as they move into earlier treatment settings. New research also suggests that resistance to CDK4/6 inhibitors involves how tumor cells regulate genes and rewire metabolism, not only new mutations. Our coverage tracks these shifts, along with new targets uncovered at AACR and a gene-edited regulatory T cell therapy heading into breast cancer trials.

Personal Folders

Create custom folders to save relevant and important content. Access and manage your saved searches and alerts.

Custom Feeds

Turn any search into a custom feed, to easily keep up on the most recent BioCentury analysis, conveniently organized by the topics of your choice.

Highlights from BioCentury's Editors

View the latest Editors' Picks. Easily access BioCentury's Daily and Weekly Editions.